Premium
Outcomes in patients with mucosal melanomas
Author(s) -
Keller Deborah S.,
Thomay Alan A.,
Gaughan John,
Olszanski Anthony,
Wu Hong,
Berger Adam C.,
Farma Jeffrey M.
Publication year - 2013
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23445
Subject(s) - medicine , mucosal melanoma , lymphovascular invasion , melanoma , lymph node , proportional hazards model , hard palate , stage (stratigraphy) , surgery , cancer , metastasis , paleontology , cancer research , biology
Background and Objective Our goal was to evaluate the different subtypes of mucosal melanoma and describe specific variables that predict outcomes. Methods Prospective review of two tertiary care center databases identified 76 mucosal melanoma patients; 73 with complete records were included. Demographic and clinical data were analyzed. Cox regression determined variables impacting recurrence and survival. Results In the 73 patients, the mean age was 64 years, and 74% were female. Sixty‐seven percent presented with lymph node involvement, and 73% had ulcerated tumors. Major sites affected were nasal/palate/oral (36%), vulvar/vaginal/cervical (48%), and anorectal (15%). Mean overall and disease‐free survival were 56.9 and 27.2 months. Variables associated with decreased survival included: lymphovascular invasion (HR17.70, P = 0.0093), Caucasian race (HR3.02, P = 0.0362), nasal/palate/oral sub‐group (HR1.85, P = 0.026), Breslow thickness (HR1.23, P = 0.00004), T stage (HR1.34, P = 0.0075), M stage (HR3.03, P = 0.0039), and chemotherapy (HR3.13, P = 0.0002). The worst prognosis was seen in the nasal/palate/oral sub‐group, with a median overall survival of 9.7 months and recurrence‐free time of 4.5 months. This subtype also demonstrated high lymph node positivity, ulceration, and larger tumor size. Conclusion The nasal, palate, oral subtype has the worst prognosis compared to other mucosal melanoma locations. Studies are ongoing to evaluate pathologic and genomic variables that may predict outcomes. J. Surg. Oncol. 2013; 108:516–520 . © 2013 Wiley Periodicals, Inc.